Connect with us

Cannabis News

Psychedelics Show Promise As An ‘Entirely New Type Of Anti-Inflammatory Treatment,’ Research Suggests

Published

4 months ago

on

“Evidence is growing in the key to managing inflammation of psychedelics, including a major driver of many chronic body diseases, depression, arthritis and heart conditions.”

Nicholas Barnes at the University of Birmingham, through dialogue

Once hippies and hallucination experiences are synonymously exploring psychedelic drugs today for their medical potential. The stigma of this era was eliminating drugs according to laws, however, moved with mental health treatments, scientists have returned to this discussed izer of medicine.

Psilocybin substances (found in magical mushrooms) and Ayahuasca are seriously taking scientists and doctors, they do not have caused perspectives, but if they have potential healing.

Initially, he focused on treating mental health conditions such as depression, which only helps the drugs prescribed today. But these studies have been expanded to internalize diseases driven by the inflammation, which can help reduce the immune system soothing.

Laboratory dishes and animal exams and animal exams, DMT, LSD can release inflammatory molecules called cytokines called cytokines. These protein molecules also rheumatoid arthritis, asthma as well as depression, in addition to increasing brain damage, after traumatic brain injury.

Advantage of steroids

But these drugs have a great advantage over the typical anti-infinite medications against steroids, because psychedelics work because it works without removing healthy immune function, which is the main problem with steroids.

Important, these lab findings are beginning to confirm in human studies. The evidence is growing the key to managing inflammation of psychedelics, including one of many chronic body diseases, including depression, arthritis and heart conditions.

Take the active ingredient in psilocybin, magic mushrooms. In a study with 60 healthy participants, only one dose was enough for two inflammatory molecule-tnf-alpha and IL-6-6-6 – next week.

However, not all studies show the same light results. Some people only had a few participants and others were complex because some participants had previous drug experience, which may affect results.

It is a great challenge to learn psychedelic in medicine research because it is very difficult to get real drugs and hide the placebo. When someone has a great psychedelic experience, it’s obvious that they didn’t take the sugar pill.

This challenges to interpret the results, especially aspects such as moods, which can significantly cause expectations. Changes in the body, too, can cause such inflammation, this placebo effect.

Meanwhile, the Amazonian Brew with the DMT psychedelic drug showed the promising results of people with hard depression and patients. In a study, those provided by Ayahuasca reduced the level of an inflammatory marker called CRP.

The higher the CRP drop, the greater the improvements in humor. This suggests that reducing inflammation can lead to improving mental health and conditions like depression and schizophrenia are related to inflammation of the body.

Scientists believe that psychedelic is especially true for 5-HT2A recipient, a part of the brain cells that usually responds to serotonin, called the “happy hormone”.

This recipient establishes a chain of chemical reactions within the cells. Here are the amazing parts: inflammatory effects against psychedelicism would not rely on the same processes that cause mind to change mind experiences, such as some calcium signals and other well-studied means. In fact, researchers believe that different mechanisms that are not understood can be involved, though yet invented.

In an analysis of the anxiety of asthma, there were two drugs with similar psychedelic effects, (R) -Do (R) -Dotfm, different results against anti-inflamity. The first drug was completely reversed swelling, and the other did nothing. This even more suggests that anti-inflammatory effects can be separated from psychedelic effects, opening the door to develop more safier medication.

The next generation of inflammatory anti-inflammatory pipi-psychedelic drug-psychedelic drugs come from I call. These are medications designed to imitate the therapeutic benefits of psychedelics, without causing hallucinations.

Several drugs have been identified, such as DLX-001 and DLX-159, Delix Therapeutics, developing the American Pharmaceutical Company. These experimental drugs show answers that represent antidepressive effects of “travel without affecting. Inflammation could be transformed into many conditions related to inflammation, without the reluctance of a regulatory complication or patient associated with psychedelic.

Although research in the early stages, evidence is being built in psychedelic or new drugs developed, can become a completely new type of inflammatory anti-inflammatory. People with long-term inflammatory diseases begin and use more stringent and innovative placebo-controlled designs, we can think of immersing the world in the world of psychedelism to be unexpected diseases.

The potential of the hallucinogenic effects flows treatment for many patients with the conditions that inflammation complies with the fundamental role.

This story first published the interview.

Photo elements courtesy CarlosemMaskypy and Apollo.

Marijuana is possible with the help of readers. If you are based on journalism to defend cannabis, consider the commitment to Patreon every month.

Become patreon guard!

Related Topics:
Continue Reading

Cannabis News

New partnership to expand greenhouse drone distribution across Europe

Published

6 hours ago

on

February 6, 2026

By

GeoCue welcomes MOST Robotics to its global distribution network. Based in Germany and serving customers throughout Germany, Austria and Switzerland, MOST Robotics will offer TrueView GO LiDAR solutions and LP360 software, from GeoCue, to surveying, construction, forestry, agricultural and industrial inspection professionals looking for a complete and reliable workflow from data capture to delivery.

Founded in 2021 by Valentin Möller and Lennart Stollberg, MOST Robotics builds on deep UAV experience since 2015, offering integrated turnkey drone and sensor solutions, supported by technical consulting and first-class customer support. Their team works closely with end users to ensure technology works in real-world conditions, from flight planning to endpoint cloud processing, a full-service company for individual solutions.

MOST Robotics is expanding its portfolio of handheld SLAM LiDAR and LP360 software to directly respond to customer needs, especially for projects where flight restrictions, dense vegetation or indoor environments make aerial collection difficult. With TrueView GO and LP360, customers can complement drone surveys with ground-based SLAM capture, process aerial LiDAR and produce high-quality photogrammetric output. This approach supports rapid and accurate classification of large data sets and the creation of highly accurate digital terrain models, helping to reduce office processing time while improving the final quality of delivery.

© MOST Robotics

Valentin Möller, CEO of MOST Robotics, commented: “GeoCue makes UAV LiDAR and SLAM bridges in a way that matches how our customers work in the real world. We spend a lot of time in the field with customers, which gives us practical feedback and clear ideas on what needs to be improved. GeoCue is open to this kind of input, and we’re excited to help shape each of our customers’ missions.”

Samuel Flick, GeoCue’s European Sales Manager, added: “We are delighted to welcome MOST Robotics to the GeoCue distribution network. Their technical depth and customer-first approach make them a strong partner as we continue to grow the LiDAR market in Europe. We look forward to supporting their team as they expand access to the TrueView product line, including aerial, handheld and LiDAR 360 mobile device software.”

For more information:
MOST robotics
https://mostrobotics.com/

GeoCue
https://geocue.com/

Continue Reading

Cannabis News

USDA-APHIS grants non-regulated status to two gene-edited hemp varieties

Published

1 day ago

on

February 5, 2026

By











USDA’s Animal and Plant Health Inspection Service (APHIS) recently issued regulatory status review responses for two new gene-edited hemp varieties, determining that they are not subject to federal regulation under 7 CFR part 340. Developed by researchers at the University of Wisconsin-Madison, these gene-edited plants have been found to have no increased risk of plant pests compared to conventional hemp. This federal clearance marks an important milestone in easing the path from laboratory to commercial cultivation of precision-bred industrial crops.

© Crop Innovation Center of Wisconsin-MadisonBadger PMR hemp variety gene-edited

Badger PMR (Dust Resistant) has full dust resistance, and Badger Zero (Cannabinoid Free) is cannabinoid free. The main innovation involves the creation of hemp varieties that are unable to produce THC (tetrahydrocannabinol), the psychoactive compound found in cannabis. Using CRISPR gene-editing technology to turn off specific genes responsible for THC production, the UW-Madison team has solved a major hurdle for the industry. This genetic certainty prevents crops from being “hot” — the term used when THC levels accidentally exceed the legal limit of 0.3 percent — which previously forced farmers to destroy entire fields to comply with federal law.

Beyond THC removal, researchers have also engineered varieties with higher concentrations of CBG (cannabigerol), a non-psychoactive cannabinoid valued for its potential therapeutic benefits. These advances are expected to stabilize the hemp market, providing growers with reliable, high-value and legal-compliant varieties. With the regulatory green light from the USDA, these precision-bred hemp lines are poised to revitalize the industry, providing a safer and more profitable future for farmers across the United States.

For more information:
International Service for the Acquisition of Agricultural Biotechnology Applications
Email: (email protected)
isaaa.org/default.asp



Publication date:













Continue Reading

Cannabis News

Kentucky Governor Announces Medical Marijuana Gummies Are Now Available, While Pushing Lawmakers To Approve New Qualifying Conditions

Published

1 day ago

on

February 5, 2026

By

Kentucky’s governor is urging lawmakers to give more patients legal access to medical marijuana, announcing that cannabis gummies can now be purchased at state-licensed dispensaries.

Gov. Andy Beshear (D) said Thursday that his administration has sent a letter urging legislative leadership to pass a bill that lists ALS, Parkinson’s disease, Crohn’s disease, sickle cell anemia, fibromyalgia, glaucoma, terminal illnesses and other conditions as conditions for medical cannabis.

“In most other states that have a medical marijuana program, these are conditions that are covered, and conditions that are deemed appropriate by our board of physicians and counselors,” he said. “Expanding the list could help the approximately 430,000 Kentuckians who currently lack access but face these challenges.”

The governor said state officials are “making great strides” in expanding the medical marijuana program to “increase access for those who are already eligible.”

“We currently have 510 registered professionals and over 18,500 approved cards, and those numbers continue to grow,” Beshear said, adding that regulators are making “steady progress” in accepting businesses at every step of the cannabis supply chain.

“As the supply chain expands, patients are starting to see more options online,” he said. “We can announce that gummies are on the market in Kentucky and showing progress in communities across Kentucky.”




The governor’s latest update comes about a month after he took the podium and said “not happy” with the time it’s taken to roll out the state’s medical marijuana program—but predicts that the pace of patient access will “significantly increase” in 2026.

Also last month, Beshear said two more dispensaries will open their doors “once additional product becomes available.” The The state’s first medical cannabis plant was launched in December.

The governor, who has long championed cannabis reform, he anticipated a market launch that monthwhile claiming that medical marijuana will help thousands of patients find an alternative to opioids for pain management.

He at the end of October it passed the milestone of registering 15,000 patientsbut that has grown significantly in recent weeks.

Beshear previously acknowledged that “it’s taken longer than we would have liked” to sustain the industry since he signed off on legalizing medical marijuana in 2023.

Considering this delayed implementation, he signed an executive order this year to waive renewal fees for patients who get the cards so that they are not charged again before the stores open. And another order he signed to provide protections for qualified patients who obtain medical marijuana outside of Kentucky “will remain in place.”

Beshear announced separately that in May the state launched a new online directory that allows people to see where medicinal cannabis will open next to them

He noted that the state is working to provide access to patients “as soon as possible,” which includes speeding up the licensing process. Last January, so did the governor ceremoniously issued the first medical marijuana cards in the commonwealth.

—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

Meanwhile, the governors sent a letter to Kentucky’s congressional delegation last yearurging them to “take decisive action to protect the constitutional rights of our law-abiding medical cannabis patients” by repealing the federal ban on possession of firearms by marijuana users.

Bipartisan Kentucky senators introduced similar legislation asked the federal representatives of the state to take corrective measuresBeshear said he agrees but would I would like to see even more significant changes at the federal level.

The federal Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) warned Kentucky residents that in 2024, if they choose to participate in the state’s medical marijuana program, they will be prohibited from buying or possessing firearms under federal law.

Health professionals have been able to Patients began to evaluate the recommendations from the beginning of last December.

While there are currently no operational dispensaries for patients, Beshear also confirmed that an executive order he signed in 2023 will be in place in the interim, protecting patients. Those with medical cannabis purchased from licensed out-of-state retailers.

In the November 2024 election, Kentucky also saw more than 100 cities and counties pass local ordinances to allow medical cannabis businesses in their jurisdictions. The governor said the election results show that “the jury is no longer out” on the issue this is clearly supported by voters across party and geographic lines.

Marihuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media